MedTrace Logo

Imaging of Solid Tumors Using DLL3 SPECT

NCT07052760 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2026-04-29

No results posted yet for this study

Summary

This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors. 111In-ABD147 is a high affinity Delta-like ligand 3 (DLL3) antigen binding domain fused to an engineered humanized Fc to create an antibody (VHH-Fc) that is bio-conjugated with a DOTA linker-chelator to a 111In radiometal. DLL3 is expressed on a variety of tumors, particularly those with neuroendocrine features.

Conditions

  • Solid Tumor Cancer
  • Castration Resistant Prostate Cancer
  • Castration Resistant Prostate Cancer (CRPC)
  • Neuroendocrine (NE) Tumors

Interventions

DRUG

111In-ABD147

Given intravenously (IV) prior to imaging

PROCEDURE

Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)

Undergo imaging

Sponsors & Collaborators

  • Abdera Therapeutics Inc.

    collaborator INDUSTRY

  • Thomas Hope

    lead OTHER

Principal Investigators

  • Thomas A Hope, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-05-31
Completion
2028-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07052760 on ClinicalTrials.gov